Translational paradigms in pharmacology and drug discovery.
暂无分享,去创建一个
[1] A. Tanay,et al. Single cell Hi-C reveals cell-to-cell variability in chromosome structure , 2013, Nature.
[2] Kathryn Moynihan Ramsey,et al. Circadian rhythms, sleep, and metabolism. , 2011, The Journal of clinical investigation.
[3] S. Vilar,et al. High-Throughput Methods for Combinatorial Drug Discovery , 2013, Science Translational Medicine.
[4] C. Plass,et al. The evolving epigenome. , 2013, Human molecular genetics.
[5] Georgina M. Mace,et al. Distorted Views of Biodiversity: Spatial and Temporal Bias in Species Occurrence Data , 2010, PLoS biology.
[6] H. Kubinyi. Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.
[7] D. Sackett. Bias in analytic research. , 1979, Journal of chronic diseases.
[8] P. Hopkins. Familial hypercholesterolemia--improving treatment and meeting guidelines. , 2003, International journal of cardiology.
[9] M. Williams,et al. Challenges in the Search for Drugs to Treat Central Nervous System Disorders , 2009, Journal of Pharmacology and Experimental Therapeutics.
[10] Chun Liu,et al. Social Influence Bias : A Randomized Experiment , 2014 .
[11] P. Sandercock,et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.
[12] Hans-Christoph Diener,et al. NXY-059 for the treatment of acute ischemic stroke. , 2007, The New England journal of medicine.
[13] Michael Williams,et al. Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century. , 2014, Biochemical pharmacology.
[14] K. Eggan,et al. Modeling human disease with pluripotent stem cells: from genome association to function. , 2013, Cell stem cell.
[15] Jean-Pierre Gillet,et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance , 2011, Proceedings of the National Academy of Sciences.
[16] D. Pisetsky,et al. DNA microarrays: boundless technology or bound by technology? Guidelines for studies using microarray technology. , 2002, Arthritis and rheumatism.
[17] D. Light,et al. Demythologizing the high costs of pharmaceutical research , 2011 .
[18] Gene W. Yeo,et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43 , 2011, Nature Neuroscience.
[19] Mathias Jucker,et al. The benefits and limitations of animal models for translational research in neurodegenerative diseases , 2010, Nature Medicine.
[20] Data production leads,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .
[21] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[22] Kenneth M. Yamada,et al. What's in a picture? The temptation of image manipulation , 2004, The Journal of cell biology.
[23] W. Cookson,et al. Genetic and genomic approaches to asthma: new insights for the origins , 2012, Current opinion in pulmonary medicine.
[24] David F. Horrobin,et al. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.
[25] Sheng Ding,et al. TARGET VALIDATION IN CHEMOGENOMICS , 2007 .
[26] J. Moreau,et al. Rodent models of insomnia: A review of experimental procedures that induce sleep disturbances , 2009, Neuroscience & Biobehavioral Reviews.
[27] J. Grotta,et al. NXY-059 for the Treatment of Acute Stroke: Pooled Analysis of the SAINT I and II Trials , 2008, Stroke.
[28] P. Bath,et al. Effects of NXY‐059 in experimental stroke: an individual animal meta‐analysis , 2009, British journal of pharmacology.
[29] D. Swinney,et al. How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.
[30] David Julius,et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.
[31] Elena Cattaneo,et al. Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.
[32] A. Casadevall,et al. Reforming Science: Methodological and Cultural Reforms , 2011, Infection and Immunity.
[33] A. Towse,et al. The R&D Cost of a New Medicine , 2012 .
[34] J. Black. Pharmacology: analysis and exploration. , 1986, British medical journal.
[35] Stephen B. Johnson,et al. Central challenges facing the national clinical research enterprise. , 2003, JAMA.
[36] D. Fanelli. How Many Scientists Fabricate and Falsify Research? A Systematic Review and Meta-Analysis of Survey Data , 2009, PloS one.
[37] N. Patterson,et al. Using Extended Genealogy to Estimate Components of Heritability for 23 Quantitative and Dichotomous Traits , 2013, PLoS genetics.
[38] S. Lazic,et al. A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.
[39] Invited commentary-Genetic prediction for common diseases. , 2012, Archives of internal medicine.
[40] H. Moses,et al. Biomedical research and health advances. , 2011, The New England journal of medicine.
[41] L. Menand. The marketplace of ideas , 2010 .
[42] Elaine Romanelli,et al. Organizational Legacy and the Internal Dynamics of Clusters: The U.S. Human Biotherapeutics Industry, 1976–2002 , 2013 .
[43] Thomas Steckler,et al. Touching on translation , 2013, Cell and Tissue Research.
[44] T. Kenakin,et al. Defining and characterizing drug/compound function. , 2014, Biochemical pharmacology.
[45] Albert Gough,et al. High-Content Screening: A New Approach to Easing Key Bottlenecks in the Drug Discovery Process , 1997 .
[46] Steven T. Corneliussen Steven T. Corneliussen. Wall Street Journal front page: "Mistakes in Scientific Studies Surge" , 2011 .
[47] A. Nagy,et al. EMBRYONIC STEM CELLS / INDUCED PLURIPOTENT STEM CELLS Concise Review : Embryonic Stem Cells Versus Induced Pluripotent Stem Cells : The Game Is On , 2011 .
[48] Thomas A Trikalinos,et al. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. , 2005, Journal of clinical epidemiology.
[49] A. Brazma,et al. Reuse of public genome-wide gene expression data , 2012, Nature Reviews Genetics.
[50] B. Ding,et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia , 2004, Journal of Medical Genetics.
[51] D. Howells,et al. Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.
[52] P. Almgren,et al. Genetic polymorphisms for estimating risk of atrial fibrillation in the general population: a prospective study. , 2012, Archives of internal medicine.
[53] Julio D. Duarte. Epigenetics Primer: Why the Clinician Should Care About Epigenetics , 2013, Pharmacotherapy.
[54] J. Maffrand,et al. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. , 1987, Thrombosis research.
[55] Michael Williams. Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges. , 2009, Biochemical pharmacology.
[56] M. Fraga,et al. Epigenetics and the environment: emerging patterns and implications , 2012, Nature Reviews Genetics.
[57] Terrence P. Kenakin,et al. A Pharmacology Primer: Theory, Application and Methods , 2004 .
[58] M. Mathews,et al. An Interview with , 2009 .
[59] A. Balmain,et al. Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[60] D. Goldstein,et al. Sequencing studies in human genetics: design and interpretation , 2013, Nature Reviews Genetics.
[61] John P A Ioannidis,et al. An epidemic of false claims. Competition and conflicts of interest distort too many medical findings. , 2011, Scientific American.
[62] Chris Anderson,et al. Beyond the Sequence , 2015 .
[63] J. Dungan,et al. Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation Sequencing , 2012 .
[64] D. E. McKinney. Saw palmetto for benign prostatic hyperplasia. , 1999, JAMA.
[65] A. Young,et al. A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.
[66] E. Spack,et al. The basics of preclinical drug development for neurodegenerative disease indications , 2009, BMC neurology.
[67] Khusru Asadullah,et al. What makes a good drug target? , 2012, Drug discovery today.
[68] Meredith Wadman,et al. NIH mulls rules for validating key results , 2013, Nature.
[69] S. Rees,et al. Principles of early drug discovery , 2011, British journal of pharmacology.
[70] Toshihiro Tanaka. The International HapMap Project , 2003, Nature.
[71] F. Marincola,et al. Expanding the perspective of translational medicine: the value of observational data , 2012, Journal of Translational Medicine.
[72] E. Nimmo,et al. Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics , 2013, Gastroenterology.
[73] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[74] K. Mullane,et al. Animal models of asthma: reprise or reboot? , 2014, Biochemical pharmacology.
[75] S. Bagshaw,et al. Novel biomarkers of AKI: the challenges of progress 'Amid the noise and the haste'. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[76] J. Ott,et al. Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.
[77] T Takahashi,et al. Traditional Chinese Medicine and Kampo: A Review from the Distant past for the Future , 2006, The Journal of international medical research.
[78] N. H. Rubin,et al. Circadian rhythm. , 1983, The Journal of investigative dermatology.
[79] Philip Cooke,et al. Regional Innovation Systems: General Findings and Some New Evidence from Biotechnology Clusters , 2002 .
[80] R. Steen. Retractions in the scientific literature: is the incidence of research fraud increasing? , 2010, Journal of Medical Ethics.
[81] Changyu Shen,et al. Survival and CTG repeat expansion in adults with myotonic dystrophy type 1 , 2011, Muscle & nerve.
[82] Martin Wehling,et al. Translatability scoring in drug development: eight case studies , 2012, Journal of Translational Medicine.
[83] T. Willson,et al. The importance of chronobiology to drug discovery , 2012, Expert opinion on drug discovery.
[84] Mark S Butler,et al. The role of natural product chemistry in drug discovery. , 2004, Journal of natural products.
[85] E. Lander,et al. The mystery of missing heritability: Genetic interactions create phantom heritability , 2012, Proceedings of the National Academy of Sciences.
[86] Jan van Gijn,et al. Acute Ischemic Stroke , 2007 .
[87] Jean Golding,et al. The search for genenotype/phenotype associations and the phenome scan. , 2005, Paediatric and perinatal epidemiology.
[88] G. Malhi,et al. Chronobiology of mood disorders , 2013, Acta psychiatrica Scandinavica. Supplementum.
[89] P. Bhargava,et al. Animal models of sleep disorders. , 2013, Comparative medicine.
[90] Péter Kakuk,et al. The Legacy of the Hwang Case: Research Misconduct in Biosciences , 2009, Sci. Eng. Ethics.
[91] J. Trojanowski,et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.
[92] T. Misteli. Beyond the Sequence: Cellular Organization of Genome Function , 2011 .
[93] K. Hochedlinger,et al. A variant CRISPR-Cas9 system adds versatility to genome engineering , 2013, Proceedings of the National Academy of Sciences.
[94] B. Deer,et al. How the case against the MMR vaccine was fixed , 2011, BMJ : British Medical Journal.
[95] Paul Morgan,et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.
[96] W. Pullman,et al. From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference , 2004, Journal of Translational Medicine.
[97] A. Mandavilli. Peer review: Trial by Twitter , 2011, Nature.
[98] John P A Ioannidis,et al. Excess significance bias in the literature on brain volume abnormalities. , 2011, Archives of general psychiatry.
[99] Thanos Athanasiou,et al. How to Read a Paper , 2010 .
[100] M. Danhof,et al. Commentary: "A systems view on the future of medicine: inspiration from Chinese medicine?". , 2009, Journal of ethnopharmacology.
[101] P. Sandercock,et al. Where is the evidence that animal research benefits humans? , 2004, BMJ : British Medical Journal.
[102] J. Vederas,et al. Drug Discovery and Natural Products: End of an Era or an Endless Frontier? , 2009, Science.
[103] M. Carskadon,et al. Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review. , 2007, Sleep.
[104] London,et al. The Rise and Fall of Modern Medicine , 2000 .
[105] D. Howells,et al. Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy , 2010, PLoS biology.
[106] Alexander Schuhmacher,et al. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective , 2012, Human Genomics.
[107] E. Dorsey,et al. Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas , 2009, PloS one.
[108] J. Holdway,et al. In vivo monitoring of cardiomyocyte proliferation to identify chemical modifiers of heart regeneration , 2013, Development.
[109] Arturo Casadevall,et al. Why Has the Number of Scientific Retractions Increased? , 2013, PloS one.
[110] F. Zitman,et al. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness , 2013, Journal of psychopharmacology.
[111] J. Couzin-Frankel. Cancer research. As questions grow, Duke halts trials, launches investigation. , 2010, Science.
[112] Michael R. Hayden,et al. Hunting human disease genes: lessons from the past, challenges for the future , 2013, Human Genetics.
[113] B. Pulverer. Science publishing: How to stop plagiarism , 2012, Nature.
[114] J. Grimshaw,et al. Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments , 2013, PLoS medicine.
[115] Michael A Fischbach,et al. New antibiotics from bacterial natural products , 2006, Nature Biotechnology.
[116] Kelly Rae Chi. Revolution dawning in cardiotoxicity testing , 2013, Nature Reviews Drug Discovery.
[117] Christine Van Broeckhoven,et al. Genetic insights in Alzheimer's disease , 2013, The Lancet Neurology.
[118] B. Aggarwal,et al. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. , 2009, Trends in pharmacological sciences.
[119] S. Vedula,et al. Restoring invisible and abandoned trials: a call for people to publish the findings , 2013, The BMJ.
[120] T. Cremer,et al. Chromosome territories, nuclear architecture and gene regulation in mammalian cells , 2001, Nature Reviews Genetics.
[121] G. Donnan,et al. 1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.
[122] Cassidy R. Sugimoto,et al. Bias in peer review , 2013, J. Assoc. Inf. Sci. Technol..
[123] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[124] Brian A. Nosek,et al. Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.
[125] B. Ruggeri,et al. Animal models of human disease: challenges in enabling translation. , 2014, Biochemical pharmacology.
[126] Fatih Ozsolak,et al. RNA sequencing: advances, challenges and opportunities , 2011, Nature Reviews Genetics.
[127] Ulrich Dirnagl,et al. Reprint: Good Laboratory Practice: Preventing Introduction of Bias at the Bench , 2009, Stroke.
[128] Donald F. Klein,et al. The loss of serendipity in psychopharmacology. , 2008, JAMA.
[129] J. Ioannidis. Extrapolating from Animals to Humans , 2012, Science Translational Medicine.
[130] Steven J. Schrodi,et al. A PheWAS approach in studying HLA-DRB1*1501 , 2013, Genes and Immunity.
[131] S. Woolf. The meaning of translational research and why it matters. , 2008, JAMA.
[132] B. E. Foreman,et al. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals , 2007, Acta Pharmacologica Sinica.
[133] J. Ioannidis,et al. Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases , 2013, PLoS biology.
[134] E. Mardis. Next-generation sequencing platforms. , 2013, Annual review of analytical chemistry.
[135] D. Newman,et al. Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.
[136] Michael J Marino,et al. The use and misuse of statistical methodologies in pharmacology research. , 2014, Biochemical pharmacology.
[137] F. Prinz,et al. Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.
[138] Vivien Marx,et al. Next-generation sequencing: The genome jigsaw , 2013, Nature.
[139] H. Wortelboer,et al. Combined Analysis of Pharmacokinetic and Efficacy Data of Preclinical Studies with Statins Markedly Improves Translation of Drug Efficacy to Human Trials , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[140] L. D. de Windt,et al. Regulation of fetal gene expression in heart failure. , 2013, Biochimica et biophysica acta.
[141] S. Finkbeiner,et al. Modeling Huntington's disease with induced pluripotent stem cells , 2013, Molecular and Cellular Neuroscience.
[142] G. Nepom,et al. Animal models of human type 1 diabetes , 2009, Nature Immunology.
[143] Rae Silver,et al. Orchestrating time: arrangements of the brain circadian clock , 2005, Trends in Neurosciences.
[144] S. Enna,et al. Defining the role of pharmacology in the emerging world of translational research. , 2009, Advances in pharmacology.
[145] R. Barker,et al. Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything? , 2012, Stem cells international.
[146] M. Rosenblatt. How academia and the pharmaceutical industry can work together: the president's lecture, annual meeting of the American Thoracic Society, San Francisco, California. , 2013, Annals of the American Thoracic Society.
[147] M. Genovese. Inhibition of p38: has the fat lady sung? , 2009, Arthritis and rheumatism.
[148] G. FitzGerald,et al. Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. , 2013, Circulation research.
[149] Gert-Jan Hospers,et al. The New Economic Geography of Old Industrial Regions: Universities as Global — Local Pipelines , 2007 .
[150] A. Feinberg,et al. Higher order chromatin organization in cancer. , 2013, Seminars in cancer biology.
[151] Gene W. Yeo,et al. Genome-Wide Approaches to Dissect the Roles of RNA Binding Proteins in Translational Control: Implications for Neurological Diseases , 2012, Front. Neurosci..
[152] M. Fisher,et al. NXY-059 for the treatment of stroke. , 2007, The New England journal of medicine.
[153] G. Marek,et al. Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. , 2011, Biochemical pharmacology.
[154] Marijn T. M. van Jaarsveld,et al. Defining Genetic Factors That Modulate Intergenerational CAG Repeat Instability in Drosophila melanogaster , 2011, Genetics.
[155] J. Shorter,et al. RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration , 2012, Neurology research international.
[156] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[157] Raymond J Winquist,et al. The fall and rise of pharmacology--(re-)defining the discipline? , 2014, Biochemical pharmacology.
[158] Kevin Kim,et al. A TALEN genome-editing system for generating human stem cell-based disease models. , 2013, Cell stem cell.
[159] Peter Elkind,et al. Inside Pfizer's palace coup. Did CEO Jeff Kindler get pushed out because he was shaking up the dysfunctional pharmaceutical giant--or because he was an ineffective leader? , 2011, Fortune.
[160] R. Cancedda,et al. An intronic ncRNA-dependent regulation of SORL1 expression affecting Aβ formation is upregulated in post-mortem Alzheimer's disease brain samples , 2012, Disease Models & Mechanisms.
[161] Fred H. Gage,et al. Induced pluripotent stem cells: the new patient? , 2012, Nature Reviews Molecular Cell Biology.
[162] S. Yamanaka. Induced pluripotent stem cells: past, present, and future. , 2012, Cell stem cell.
[163] C. Ball,et al. Repeatability of published microarray gene expression analyses , 2009, Nature Genetics.
[164] Thomas Hankemeier,et al. Systems biology-based diagnostic principles as pillars of the bridge between Chinese and Western medicine. , 2010, Planta medica.
[165] Calliope A. Dendrou,et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis , 2012, Nature.
[166] Peter Imming,et al. Drugs, their targets and the nature and number of drug targets , 2007, Nature Reviews Drug Discovery.
[167] H. Calkins,et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs , 2012, Nature.
[168] R. Gamelli,et al. Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013, Proceedings of the National Academy of Sciences.
[169] Hugues Dolgos,et al. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. , 2009, Drug discovery today.
[170] D. Bylund,et al. Quantitative versus qualitative data: the numerical dimensions of drug action. , 2014, Biochemical pharmacology.
[171] Patricia M. LoRusso,et al. Phase 0 clinical trials: an answer to drug development stagnation? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[172] Teri A. Manolio,et al. Bringing genome-wide association findings into clinical use , 2013, Nature Reviews Genetics.
[173] Gonçalo R. Abecasis,et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma , 2007, Nature.
[174] Shane J. Neph,et al. Systematic Localization of Common Disease-Associated Variation in Regulatory DNA , 2012, Science.
[175] James Le Fanu,et al. The Rise and Fall of Modern Medicine , 1999 .
[176] Krishna Kodukula,et al. Biomarkers in pharmacology and drug discovery. , 2014, Biochemical pharmacology.
[177] E. Maywood,et al. Circadian clocks: regulators of endocrine and metabolic rhythms. , 2007, The Journal of endocrinology.
[178] Curtis J Henrich,et al. Matching the power of high throughput screening to the chemical diversity of natural products. , 2013, Natural product reports.
[179] John Higgins,et al. Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure. , 2012, Drug discovery today.
[180] M. Kitazawa. Circadian Rhythms, Metabolism, and Insulin Sensitivity: Transcriptional Networks in Animal Models , 2013, Current Diabetes Reports.
[181] David J Newman,et al. Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.
[182] Youssef L Bennani,et al. Drug discovery in the next decade: innovation needed ASAP. , 2012, Drug discovery today.
[183] C. Begley,et al. Drug development: Raise standards for preclinical cancer research , 2012, Nature.
[184] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[185] Ueli Schibler,et al. Circadian rhythms: mechanisms and therapeutic implications. , 2007, Annual review of pharmacology and toxicology.
[186] D. Braff,et al. The neuropsychiatric translational revolution: still very early and still very challenging. , 2013, JAMA psychiatry.
[187] Richard Morphy,et al. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .
[188] J. Ioannidis. Why Science Is Not Necessarily Self-Correcting , 2012, Perspectives on psychological science : a journal of the Association for Psychological Science.
[189] J. Brooks. Why most published research findings are false: Ioannidis JP, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece , 2008 .
[190] K. Coombes,et al. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology , 2009, 1010.1092.
[191] B. Cravatt,et al. Determining target engagement in living systems. , 2013, Nature chemical biology.
[192] D. DeMets,et al. Data integrity. , 2020, Controlled clinical trials.
[193] R. Myers,et al. Quality assessment of the human genome sequence , 2004, Nature.
[194] Michael P. Snyder,et al. Extensive genetic variation in somatic human tissues , 2012, Proceedings of the National Academy of Sciences.
[195] Miles Parkes,et al. Genetic insights into common pathways and complex relationships among immune-mediated diseases , 2013, Nature Reviews Genetics.
[196] Birgit Schoeberl,et al. An expanding role for cell biologists in drug discovery and pharmacology , 2012, Molecular biology of the cell.
[197] Katriina Aalto-Setälä,et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture , 2011, Disease Models & Mechanisms.
[198] Joost C M Uitdehaag. The seven types of drug discovery waste: toward a new lean for the drug industry. , 2011, Drug discovery today.
[199] B. Ploeger,et al. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives. , 2013, Drug discovery today.
[200] J. Ioannidis,et al. Quantifying Selective Reporting and the Proteus Phenomenon for Multiple Datasets with Similar Bias , 2011, PloS one.
[201] T Misteli,et al. Protein dynamics: implications for nuclear architecture and gene expression. , 2001, Science.
[202] Anirban Basu,et al. A CTSA Agenda to Advance Methods for Comparative Effectiveness Research , 2011, Clinical and translational science.
[203] Y. Lazebnik. Can a biologist fix a radio? — or, what I learned while studying apoptosis , 2004, Biochemistry (Moscow).
[204] H. Hobbs,et al. Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective low density lipoprotein receptors. , 1989, The Journal of clinical investigation.
[205] U. Dirnagl,et al. Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study Quality , 2008, Stroke.
[206] Laraine T. Zappert,et al. In the pipeline , 1985 .
[207] Sydney Brenner,et al. An interview with... Sydney Brenner. Interview by Errol C. Friedberg. , 2008, Nature reviews. Molecular cell biology.
[208] Michael Williams,et al. Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences? , 2011, Journal of Pharmacology and Experimental Therapeutics.
[209] J. Loscalzo. Irreproducible experimental results: causes, (mis)interpretations, and consequences. , 2012, Circulation.
[210] P. Clemons,et al. Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.
[211] Marylyn D. Ritchie,et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations , 2010, Bioinform..
[212] P. Marjoram,et al. Post-GWAS: where next? More samples, more SNPs or more biology? , 2013, Heredity.
[213] M. Esteller. Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.
[214] Experimental Irreproducibility: Causes, (Mis)interpretations, and Consequences , 2012 .
[215] K. Blennow,et al. Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease , 2010, Alzheimer's Research & Therapy.
[216] Ben R. Martin,et al. Whither research integrity? Plagiarism, self-plagiarism and coercive citation in an age of research assessment , 2013 .
[217] E. Lander. Initial impact of the sequencing of the human genome , 2011, Nature.
[218] S. Goineau,et al. Overview of Safety Pharmacology , 2013, Current protocols in pharmacology.
[219] Karla K Kopec,et al. Target identification and validation in drug discovery: the role of proteomics. , 2005, Biochemical pharmacology.
[220] C Kooperberg,et al. The use of phenome‐wide association studies (PheWAS) for exploration of novel genotype‐phenotype relationships and pleiotropy discovery , 2011, Genetic epidemiology.
[221] Kennon Heard,et al. Emergency medicine animal research: does use of randomization and blinding affect the results? , 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[222] G. Joos,et al. Targeting interleukin-4 in asthma: lost in translation? , 2012, American journal of respiratory cell and molecular biology.
[223] D. Altshuler,et al. Validating therapeutic targets through human genetics , 2013, Nature Reviews Drug Discovery.
[224] J. Scannell,et al. Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.
[225] F. Collins,et al. A vision for the future of genomics research , 2003, Nature.
[226] M. Rotger,et al. Pharmacogenomics: What is Next? , 2011, Front. Pharmacol..
[227] D. Eyding,et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials , 2010, BMJ : British Medical Journal.
[228] F. Collins. Has the revolution arrived? , 2010, Nature.
[229] A. Casadevall,et al. Misconduct accounts for the majority of retracted scientific publications , 2012, Proceedings of the National Academy of Sciences.
[230] W. Busse,et al. Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases. , 2012, The Journal of allergy and clinical immunology.
[231] Markus Grammel,et al. Chemical reporters for biological discovery. , 2013, Nature chemical biology.
[232] D C Swinney,et al. Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines , 2013, Clinical pharmacology and therapeutics.
[233] M. Ritskes-Hoitinga,et al. Progress in Using Systematic Reviews of Animal Studies to Improve Translational Research , 2013, PLoS medicine.
[234] K. Mullane,et al. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? , 2013, Biochemical pharmacology.
[235] A. Casadevall,et al. Reforming Science: Structural Reforms , 2011, Infection and Immunity.
[236] Mark E Bunnage,et al. Target validation using chemical probes. , 2013, Nature chemical biology.
[237] Jacob A. Tennessen,et al. Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes , 2012, Science.
[238] M. Wehling. Drug development in the light of translational science: shine or shade? , 2011, Drug discovery today.
[239] D. Sall,et al. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. , 2012, Journal of medicinal chemistry.
[240] B. Ruggeri,et al. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. , 2014, Biochemical pharmacology.
[241] Nicholas Eriksson,et al. Comparison of Family History and SNPs for Predicting Risk of Complex Disease , 2012, PLoS genetics.
[242] M. Bracken. Why animal studies are often poor predictors of human reactions to exposure , 2009, Journal of the Royal Society of Medicine.
[243] Arturo Casadevall,et al. Lost in Translation—Basic Science in the Era of Translational Research , 2009, Infection and Immunity.
[244] Suzanne K. Linder,et al. A Survey on Data Reproducibility in Cancer Research Provides Insights into Our Limited Ability to Translate Findings from the Laboratory to the Clinic , 2013, PloS one.
[245] M. Lyon. An Interview With... , 2004, Nature Reviews Genetics.
[246] K. Mullane,et al. Translational semantics and infrastructure: another search for the emperor's new clothes? , 2012, Drug discovery today.
[247] F. Pammolli,et al. The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.
[248] Andrew Hughes,et al. Model-based drug discovery: implementation and impact. , 2013, Drug discovery today.
[249] J. Mehlsen,et al. The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. , 2006, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[250] T. Tokuyasu,et al. Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus , 2012, Proceedings of the National Academy of Sciences.
[251] P. Mcgonigle. Animal models of CNS disorders. , 2014, Biochemical pharmacology.
[252] Francis Lévi,et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. , 2007, Advanced drug delivery reviews.
[253] John P. A. Ioannidis,et al. An epidemic of false claims. , 2011 .
[254] J. Weissenbach,et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.
[255] W. Eaton,et al. Epidemiology of schizophrenia: review of findings and myths. , 2007, The Psychiatric clinics of North America.
[256] How do the top 12 pharmaceutical companies operate safety pharmacology? , 2012, Journal of pharmacological and toxicological methods.
[257] Marc Vandemeulebroecke,et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.
[258] Martin Wehling,et al. Assessing the translatability of drug projects: what needs to be scored to predict success? , 2009, Nature Reviews Drug Discovery.
[259] D. Blumenthal,et al. The benefits of health information technology: a review of the recent literature shows predominantly positive results. , 2011, Health affairs.
[260] Torsten Kluba,et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. , 2013, Cell stem cell.
[261] Federico M Goodsaid,et al. Strategic paths for biomarker qualification. , 2008, Toxicology.
[262] U. Dirnagl,et al. REPRINT: Good Laboratory Practice: Preventing Introduction of Bias at the Bench , 2009, International journal of stroke : official journal of the International Stroke Society.
[263] I. Cuthill,et al. Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals , 2009, PloS one.
[264] Errol C. Friedberg,et al. Sydney Brenner , 2008, Nature Reviews Molecular Cell Biology.
[265] Christopher M. Kirchhoff,et al. Columbia Accident Investigation Board. Volume 4 , 2003 .
[266] L. Criswell,et al. Emerging patterns of genetic overlap across autoimmune disorders , 2012, Genome Medicine.
[267] R Hill,et al. NK1 (substance P) receptor antagonists--why are they not analgesic in humans? , 2000, Trends in pharmacological sciences.
[268] Etienne Weiss,et al. Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.
[269] Peter A. Jones,et al. Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.
[270] F. Godlee,et al. Wakefield’s article linking MMR vaccine and autism was fraudulent , 2011, BMJ : British Medical Journal.
[271] Martin Wehling,et al. Translational medicine: can it really facilitate the transition of research “from bench to bedside”? , 2006, European Journal of Clinical Pharmacology.
[272] D. Webb. Animal models of human disease: inflammation. , 2014, Biochemical pharmacology.
[273] Robert M. Rydzewski,et al. Real World Drug Discovery: A Chemist's Guide to Biotech and Pharmaceutical Research , 2008 .
[274] L. Studer,et al. Identification of Compounds that Rescue IKBKAP Expression in Familial Dysautonomia-iPS Cells , 2012, Nature Biotechnology.
[275] J. Lupski. Genome Mosaicism—One Human, Multiple Genomes , 2013, Science.
[276] John P. A. Ioannidis,et al. This I believe in genetics: discovery can be a nuisance, replication is science, implementation matters , 2013, Front. Genet..
[277] Jeanette J McCarthy,et al. Genomic Medicine: A Decade of Successes, Challenges, and Opportunities , 2013, Science Translational Medicine.